Country: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
NEVIRAPINE (UNII: 99DK7FVK1H) (NEVIRAPINE - UNII:99DK7FVK1H)
Camber Pharmaceuticals, Inc.
NEVIRAPINE
NEVIRAPINE 200 mg
ORAL
PRESCRIPTION DRUG
Nevirapine tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 15 days and older [see Clinical Studies (14.1, 14.2)] . Limitations of Use: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine tablets are not recommended to be initiated, unless the benefit outweighs the risk, in: - adult females with CD4 + cell counts greater than 250 cells/mm 3 or - adult males with CD4 + cell counts greater than 400 cells/mm3 [see Warnings and Precautions (5.1)] . Nevirapine tablets are contraindicated: - in patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment [see Warnings and Precautions
Nevirapine Tablets, USP 200 mg, Off-white to pale yellow colored, capsule shaped, biconvex tablets debossed with ‘H’ on one side and ‘7’ on other side with a break line on both sides. Nevirapine Tablets, USP are supplied in bottles of 60 tablets (NDC 68554-3005-0), 100 tablets (NDC 68554-3005-1), 500 tablets (NDC 68554-3005-2), 1000 tablets (NDC 68554-3005-3) Dispense in tight container as defined in the USP/NF. Storage
Abbreviated New Drug Application
Camber Pharmaceuticals, Inc. ---------- SPL MEDGUIDE SECTION Nevirapine (neh-VEER-ah-pine) Tablets, USP What is the most important information I should know about nevirapine tablets? Nevirapine tablets can cause severe liver and skin problems that may lead to death. These problems can happen at any time during treatment, but your risk is higher during the first 18 weeks of treatment. Nevirapine tablets can cause serious side effects, including: • Severe liver problems. Some people taking nevirapine tablets may develop severe liver problems that can lead to liver failure and the need for a liver transplant, or death. If you have liver problems, you may get a rash. o Women have a higher risk of developing liver problems during treatment with nevirapine tablets than men. o People who have abnormal liver test results before starting nevirapine tablets and people with hepatitis B or C also have a greater risk of getting liver problems. People who have higher CD4 + cell counts when they begin nevirapine tablets have a higher risk of liver problems, especially: o Women with CD4 + counts higher than 250 cells/mm 3. This group has the highest risk. o Men with CD4 + counts higher than 400 cells/mm 3. Stop taking nevirapine tablets and call your doctor right away if you have any of the following symptoms of liver problems with or without a skin rash: • dark (tea colored) urine • yellowing of your skin or whites of your eyes • light-colored bowel movements (stools) • fever • feeling sick to your stomach (nausea) • feel unwell or like you have the flu • pain or tenderness on your right side below your ribs • tiredness • loss of appetite • Severe skin reactions and rash. Some skin reactions and rashes may be severe, life-threatening, and in some people, may lead to death. Most severe skin reactions and rashes happen in the first 6 weeks of treatment with nevirapine tablets. o Women have a higher risk of developing a rash during treatment with nevirapine tablets than men. Stop taking nevirapine tablets and সম্পূর্ণ নথি পড়ুন
NEVIRAPINE - NEVIRAPINE TABLET CAMBER PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE NEVIRAPINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR NEVIRAPINE TABLETS. NEVIRAPINE TABLETS, USP FOR ORAL USE. INITIAL U.S. APPROVAL: 1996 WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY AND SKIN REACTIONS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING. _ FATAL AND NON-FATAL HEPATOTOXICITY HAVE BEEN REPORTED IN PATIENTS TAKING NEVIRAPINE TABLETS. DISCONTINUE IMMEDIATELY IF CLINICAL HEPATITIS OR TRANSAMINASE ELEVATIONS COMBINED WITH RASH OR OTHER SYSTEMIC SYMPTOMS OCCUR. DO NOT RESTART NEVIRAPINE TABLETS AFTER RECOVERY. ( 5.1) FATAL AND NON-FATAL SKIN REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, AND HYPERSENSITIVITY REACTIONS, HAVE BEEN REPORTED. DISCONTINUE IMMEDIATELY IF SEVERE SKIN REACTIONS, HYPERSENSITIVITY REACTIONS, OR ANY RASH WITH SYSTEMIC SYMPTOMS OCCUR. CHECK TRANSAMINASE LEVELS IMMEDIATELY FOR ALL PATIENTS WHO DEVELOP A RASH IN THE FIRST 18 WEEKS OF TREATMENT. DO NOT RESTART NEVIRAPINE TABLETS AFTER RECOVERY. ( 5.2) MONITORING DURING THE FIRST 18 WEEKS OF THERAPY IS ESSENTIAL. EXTRA VIGILANCE IS WARRANTED DURING THE FIRST 6 WEEKS OF THERAPY, WHICH IS THE PERIOD OF GREATEST RISK OF THESE EVENTS. ( 5.1, 5.2) INDICATIONS AND USAGE Nevirapine tablet is an NNRTI indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 15 days and older. ( 1) Limitations of Use: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine tablet is not recommended to be initiated, unless the benefit outweighs the risk, in: adult females with CD4 cell counts greater than 250 cells/mm adult males with CD4 cell counts greater than 400 cells/mm ( 1, 5.1) DOSAGE AND ADMINISTRATION The 14-day lead-in period must be strictly foll সম্পূর্ণ নথি পড়ুন